Fusion IP

Fusion IP plc was a pioneering intellectual property commercialisation company based in the United Kingdom, primarily focused on transforming cutting-edge research from the University of Sheffield and Cardiff University into viable spin-out businesses. Established with a unique model, Fusion IP acquired rights to university-generated intellectual property and then actively participated in the creation and development of new companies around these innovations. The company was listed on the London Stock Exchange's AIM market, raising capital to fund its operations and investments in its growing portfolio.

Fusion IP's operational model differed from traditional venture capital firms. Instead of making external investments, it acted more as an incubator and holding company, taking significant equity stakes in its spin-out ventures from inception, often in exchange for IP rights. It then provided subsequent cash injections to these companies to fuel their growth. For instance, in 2010, Fusion IP invested £250,000 into Phase Focus Limited, a University of Sheffield spin-out, and in 2011, it injected £200,000 into Medella Therapeutics Limited, a Cardiff University spin-out. These early cash infusions were critical for the development of their portfolio companies.

By 2013, Fusion IP had built a portfolio comprising 19 companies, demonstrating its commitment to nurturing a diverse range of technology and life science ventures. Its success culminated in its acquisition by IP Group plc in 2014, in an all-share deal valued at approximately £87.6 million. Following this acquisition, Fusion IP ceased to operate as an independent investment entity, with its assets and operations integrated into IP Group, a larger player in the university commercialisation space. Therefore, its historical investment activities and "first cheque" sizes reflect its specific model of internal spin-out funding rather than external venture capital deployment.